Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News EUFEPS Network on Dermatopharmacy just founded 22nd PKPD Expertentreffen in the heart of the Black Forest 3rd GBHI in Amsterdam: lively discussions and intensive exchange with authorities Meet us in Amsterdam: 3rd GBHI Conference starts soon (12 – 13 April 2018) Meet us in Munich: AGAH Annual Meeting 26 – 27 April 2018 Regorafenib: first in human as eye drops Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Experience Patch adhesion Macular MCID Investigators brochure Glaucoma Ovulation inhibition Ophthalmologist Asthma HPA axis Patients Intensive assessment station Sore throat Expert ICF Children Centralised procedure Phase I Unit Feasibility CDM Sequential designs Sample size estimation SDV Standard operating procedure Safety Central surveillance system Allergy Contraception Dry powder inhaler First in human EMA CDSIC Phase II In vitro in vivo correlation Training Pragmatism Oncology Pharmacokinetics PASS Biometrics Authorities Cough Clinical study Pharmacology Life cycle management Edema Biopharmaceutical Project Management Absorption Quality Assurance HRT Post authorisation Pharmacodynamic studies Phase I SAS Clinical Monitoring DUS Referral system Pituitary Consultancy Legal representative Axis Bioavailability Inhalatives Design development CRF Pilot study Bioequivalence Non interventional Network Oncologic network Biopharmaceutics Immunogenicity Hormone replacement therapy Product development Gynaecological trials Steady state Data Validation Plan Dry eye Patch FIM Thuringia Uveitis Charcoal Protocol Biosimilars Clinical trials Adrenocortical GCP Phase IV SocraTec C&S Rhine Main area Copyright Dose linearity FDA Standardisation Anaesthesiologist Transdermal therapeutic system Scientific expertise Scientific advice Inspection Ocular tolerability Drug Food Interaction Highly variable drugs Protocol development Slit lamp microscopy PAES OTC GLP COPD Clinical development program Elpro SOP based CDISC MMM Oncological patients Statistical Analysis Plan WinNonlin Good Clinical Practice CRO Endpoint TTS IMPD Local tolerability Efficacy Phase III Statistical services Quality Quality Management System Data Management Plan Lung Xerostomia Absorption windows Early phase Subcontractor qualification Healthy subjects Postmenopausal women HTA DDI Statistical programming Phase IIa trials Audit IEC DFI Ophthalmological trials GCP training Recruitment rates ADAM Pharmacokintetics Patient recruitment Informed Consent Procedure Monitoring US FDA Degeneration Paediatricians Ophthalmology ANVISA Source Data Verification Pulse oximetry plethysmography Common cold Sensitisation trials Drug Drug Interaction US CFR 21 Part 11 Eye disease Auditing Competence CRA Creativity Metered dose inhaler Database IB MDI Data management Cardiovascular surveillance AGAH Phase IIb trials NIS Hypothalamic Female adolescents Clinical pharmacology unit IVIVC DPI Spacious archive Legal Information Dermal irritation CDASH  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page